Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ACADIA PHARMACEUTICALS INC | Executive VP, Research & Dev | Restricted Stock Units | 50.7K | $1.52M | $29.96 | Feb 10, 2023 | Direct |
AVADEL PHARMACEUTICALS PLC | Chief Medical Officer | Stock Option (Right to Buy) | 275K | Feb 14, 2022 | Direct | ||
ACADIA PHARMACEUTICALS INC | Executive VP, Research & Dev | Non-Qualified Stock Option (Right to Buy) | 237K | Feb 10, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ACAD | ACADIA PHARMACEUTICALS INC | Feb 10, 2023 | 2 | $0 | 4 | Feb 13, 2023 | Executive VP, Research & Dev |
ACAD | ACADIA PHARMACEUTICALS INC | Feb 1, 2023 | 0 | $0 | 3 | Feb 13, 2023 | Executive VP, Research & Dev |
AVDL | AVADEL PHARMACEUTICALS PLC | Feb 14, 2022 | 1 | $0 | 4 | Feb 16, 2022 | Chief Medical Officer |
AVDL | AVADEL PHARMACEUTICALS PLC | Feb 14, 2022 | 0 | $0 | 3 | Feb 16, 2022 | Chief Medical Officer |